Literature DB >> 23355622

Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.

Marvin B Brooks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23355622      PMCID： PMC3556266          DOI： 10.1634/theoncologist.2012-0219

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  32 in total

1.  Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.

Authors:  Daniel B Costa; Mark S Huberman
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

2.  Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation.

Authors:  Bin Yan; Huili Wang; Zahid N Rabbani; Yulin Zhao; Wenrong Li; Yuqing Yuan; Fang Li; Mark W Dewhirst; Chuan-Yuan Li
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

Review 3.  Role of proinflammatory cytokines in the pathophysiology of osteoarthritis.

Authors:  Mohit Kapoor; Johanne Martel-Pelletier; Daniel Lajeunesse; Jean-Pierre Pelletier; Hassan Fahmi
Journal:  Nat Rev Rheumatol       Date:  2010-11-30       Impact factor: 20.543

4.  Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model.

Authors:  Beatriz Pagán; Angel A Isidro; Myrella L Cruz; Yuan Ren; Domenico Coppola; Jie Wu; Caroline B Appleyard
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

Review 5.  What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

Authors:  Michael H Weisman
Journal:  J Rheumatol Suppl       Date:  2002-09

6.  Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data.

Authors:  Alexander Mitsos; Ioannis N Melas; Paraskeuas Siminelakis; Aikaterini D Chairakaki; Julio Saez-Rodriguez; Leonidas G Alexopoulos
Journal:  PLoS Comput Biol       Date:  2009-12-04       Impact factor: 4.475

Review 7.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Authors:  Jasvinder A Singh; Robin Christensen; George A Wells; Maria E Suarez-Almazor; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Elizabeth Tanjong Ghogomu; Peter Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

8.  Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives.

Authors:  B Bresnihan
Journal:  Clin Exp Rheumatol       Date:  2002 Sep-Oct       Impact factor: 4.473

Review 9.  The IL-1 family and inflammatory diseases.

Authors:  C A Dinarello
Journal:  Clin Exp Rheumatol       Date:  2002 Sep-Oct       Impact factor: 4.473

10.  Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification.

Authors:  Gust Verbruggen; Ruth Wittoek; Bert Vander Cruyssen; Dirk Elewaut
Journal:  Ann Rheum Dis       Date:  2011-11-29       Impact factor: 19.103
View more
  6 in total

1.  Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies.

Authors:  Sanjoy Das; Bireswar Bhattacharya; Biplajit Das; Bibek Sinha; Taison Jamatia; Kishan Paul
Journal:  Indian J Surg Oncol       Date:  2019-08-19

2.  Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib.

Authors:  Sejeong Park; Soyoung Park; Hana Choi; Ji Young Park; Hyo Seok Lim; Myung Jae Park; Si-Young Kim
Journal:  Korean J Intern Med       Date:  2016-11-25       Impact factor: 2.884

3.  Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer.

Authors:  Jin Sheng; Wenfeng Fang; Xia Liu; Shan Xing; Jianhua Zhan; Yuxiang Ma; Yan Huang; Ningning Zhou; Hongyun Zhao; Li Zhang
Journal:  Onco Targets Ther       Date:  2017-02-21       Impact factor: 4.147

4.  Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.

Authors:  Deborah Ayeni; Braden Miller; Alexandra Kuhlmann; Ping-Chih Ho; Camila Robles-Oteiza; Mmaserame Gaefele; Stellar Levy; Fernando J de Miguel; Curtis Perry; Tianxia Guan; Gerald Krystal; William Lockwood; Daniel Zelterman; Robert Homer; Zongzhi Liu; Susan Kaech; Katerina Politi
Journal:  J Immunother Cancer       Date:  2019-07-10       Impact factor: 12.469

Review 5.  Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes.

Authors:  Mohammad Althubiti
Journal:  Saudi J Med Med Sci       Date:  2022-09-07

Review 6.  Apoptosis in Type 2 Diabetes: Can It Be Prevented? Hippo Pathway Prospects.

Authors:  Agnieszka Kilanowska; Agnieszka Ziółkowska
Journal:  Int J Mol Sci       Date:  2022-01-07       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.